Lilly's AI capability outranks Insilico's own

“the Takeda deal lets the company scale beyond its own pipeline and become a top global player in AI drug discovery”

“points to Insilico's thirty one developmental candidates as proof its platform delivers real drugs, not just software”

“roughly sixty million upfront with the remaining six hundred million tied to milestones and royalties”

“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”

“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”

“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”